Contemporary Approaches in Targeting Angiogenesis

prIME Oncology invites you to participate in “Expert Perspectives in Oncology: Contemporary Approaches in Targeting Angiogenesis,” a six-part CME-certified series with interviews and downloadable slides featuring expert perspectives from international thought leaders.

Features

		Expert Interviews
		Navigate by Topic
		Downloadable Slides

Topics

Module One: Concepts in Angiogenesis Inhibition
Module Two: Biomarkers in Angiogenesis
Module Three: Optimizing Outcomes with Antiangiogenic Therapy in Non-Small Cell Lung Cancer
Module Four: Optimizing Outcomes with Antiangiogenic Therapy in Colorectal Cancer
Module Five: Optimizing Outcomes with Antiangiogenic Therapy in Glioblastoma
Module Six: Practical Considerations in Patient Management Involving Antiangiogenic Therapy

Contemporary Approaches in Targeting Angiogenesis

Release Date
March 08, 2011

Expiration Date
March 08, 2012

Sponsorship Statement
This activity is sponsored by prIME Oncology.

Accreditation Statement
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
prIME Oncology designates this enduring Internet-based activity for maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

Concepts in Angiogenesis Inhibition (McDonald/Perez-Soler) [2010593-1]: 0.5 CME credits
Biomarkers in Angiogenesis (McDonald/Van Cutsem) [2010593-2]: 0.25 CME credits
Optimizing Outcomes with Antiangiogenic Therapy in Non-Small Cell Lung Cancer (Barlesi/Reck) [2010593-3]: 0.5 CME credits
Optimizing Outcomes with Antiangiogenic Therapy in Colorectal Cancer (Kozloff/Van Cutsem) [2010593-4]: 0.5 CME credits
Optimizing Outcomes with Antiangiogenic Therapy in Glioblastoma (Chamberlain/Weller) [2010593-5]: 0.25 CME credits
Practical Considerations in Patient Management Involving Antiangiogenic Therapy (Katz/Kozloff) [2010593-6]: 0.5 CME credits

Faculty
Fabrice Barlesi, MD, PhD
University Mediterranée
Marseille, France

Marc Chamberlain, MD
Seattle Cancer Care Alliance
Seattle, Washington, United States

Artur Katz, MD
Sirio Libanes Hospital
São Paulo, Brazil

Mark Kozloff, MD
Ingalls Hospital
Harvey, Illinois, United States

Donald McDonald, MD, PhD
University of California, San Francisco
San Francisco, California, United States

Román Pérez-Soler, MD
Montefiore Medical Center
New York, New York, United States

Martin Reck, MD, PhD
Hospital Grosshansdorf
Grosshansdorf, Germany

Eric Van Cutsem, MD, PhD
University Hospital Gasthuisberg/Leuven
Leuven, Belgium

Michael Weller, MD
University Hospital of Zurich
Zurich, Switzerland

Target Audience
This educational activity is designed for medical oncologists and other healthcare providers involved and/or interested in the utility of antiangiogenic therapy in the management of solid tumors, specifically colorectal cancer, non-small cell lung cancer (NSCLC), and glioblastoma.

Overview
International oncology experts engage in discussion and review updated clinical information regarding antiangiogenic strategies for the management of colorectal cancer, NSCLC, and glioblastoma. Downloadable slides relating to the expert discussion are also available.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

Compare and contrast the mechanism of action, efficacy, and tolerability of various antiangiogenic agents and regimens containing antiangiogenic agents.
Assess clinical endpoints for clinical trials investigating antiangiogenic therapies
Discuss ongoing research intended to individualize approaches to the utilization of antiangiogenic therapy for various malignancies
Evaluate the appropriate clinical implementation of antiangiogenic agents based on available data
Review and consider the potential role of antiangiogenic agents for specific malignancies based on the clinical development programs and available preclinical data.

Method of Participation
There are no fees for participation in and receiving continuing medical education (CME) credits for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you.

Links to the post tests are available on the video player pages.

Technical Requirements
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the Internet.

Estimated time to complete activity: 2.5 hours

Support Statement
Support for this activity has been provided by an unrestricted educational grant from F. Hoffmann-La Roche Ltd.

Disclosure of Conflicts of Interest
In accordance with the ACCME standards for Commercial Support, educational activities sponsored by prIME Oncology must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a prIME Oncology-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

FACULTY

Dr Barlesi has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd. He received fees for non-CME services from F. Hoffmann-La Roche Ltd. He has also performed contracted research for F. Hoffmann-La Roche Ltd. None of these relationships will impact his ability to present an unbiased discussion.

Dr Chamberlain has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd; Merck & Co., Inc; Exelixis; and Sigma Tau Pharmaceuticals. Also he received fees for non-CME services from F. Hoffmann-La Roche Ltd; Merck & Co., Inc; Exelixis; and Sigma Tau Pharmaceuticals. None of these relationships will impact his ability to present an unbiased discussion.

Dr Katz has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd, Pfizer Inc, and AstraZeneca Pharmaceuticals. Also he received fees for non-CME services from F. Hoffmann-La Roche Ltd, Pfizer Inc, and AstraZeneca Pharmaceuticals. None of these relationships will impact his ability to present an unbiased discussion.

Dr Kozloff has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd, and Genentech. Also he received fees for non-CME services from F. Hoffmann-La Roche Ltd, and Genentech. Neither of these relationships will impact his ability to present an unbiased discussion.

Dr McDonald has disclosed that he does not have any real or apparent conflicts of interest to report.

Dr Perez-Soler has disclosed that he has received consulting fees from Eli Lilly and Company, Genentech BioOncology, and F. Hoffmann-La Roche Ltd. None of these relationships will impact his ability to present an unbiased discussion..

Dr Reck has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd, Eli Lilly and Company, AstraZeneca Pharmaceuticals, and Pfizer Inc. Also he received fees for non-CME services from F. Hoffmann-La Roche Ltd, Eli Lilly and Company, AstraZeneca Pharmaceuticals, and Merck & Co., Inc. None of these relationships will impact his ability to present an unbiased discussion.

Dr van Cutsem has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd, Merck Serono, and Amgen Inc. He has also performed contracted research for F. Hoffmann-La Roche Ltd, Merck Serono, and Amgen Inc. None of these relationships will impact his ability to present an unbiased discussion.

Dr Weller has disclosed that he has received CME consulting fees from F. Hoffmann-La Roche Ltd, Merck Serono, and Merck Sharp & Dohme Limited. He has also performed contracted research for F. Hoffmann-La Roche Ltd, and Merck Serono. None of these relationships will impact his ability to present an unbiased discussion.

PLANNERS
Nathan Kelly, PhD (clinical) – no real or apparent conflicts of interest
Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
Susan H. Yarbrough, CCMEP (compliance) – no real or apparent conflicts of interest

Disclosure of Unlabeled Use
Participants have implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.